{"log_id": 5617027199093539793, "direction": 0, "words_result_num": 42, "words_result": [{"probability": {"variance": 4.3e-05, "average": 0.997884, "min": 0.957294}, "location": {"width": 810, "top": 226, "height": 36, "left": 204}, "words": "研究0102和0103中开放性富马酸替诺福韦二吡呋酯治疗期间(第48~240周),有"}, {"probability": {"variance": 0.002278, "average": 0.984805, "min": 0.733007}, "location": {"width": 810, "top": 259, "height": 28, "left": 205}, "words": "不足1%受试者(5/585)出现确证的血清肌酐相对基线升高0.5mg/dL。持续治疗240"}, {"probability": {"variance": 0, "average": 0.999488, "min": 0.997833}, "location": {"width": 418, "top": 289, "height": 27, "left": 205}, "words": "周期间,未观察到耐受性特征发生显著变化"}, {"probability": {"variance": 4.2e-05, "average": 0.997728, "min": 0.959727}, "location": {"width": 811, "top": 339, "height": 33, "left": 205}, "words": "实验室异常结果:截至第48周时,3级和4级实验室检查异常总结见表8。上述研究"}, {"probability": {"variance": 0.002554, "average": 0.989825, "min": 0.675643}, "location": {"width": 832, "top": 370, "height": 31, "left": 205}, "words": "中持续富马酸替诺福韦二吡呋酯治疗240周受试者出现的3/4级实验室异常结果相似。"}, {"probability": {"variance": 6.2e-05, "average": 0.984726, "min": 0.976876}, "location": {"width": 51, "top": 444, "height": 26, "left": 204}, "words": "表8"}, {"probability": {"variance": 0.01005, "average": 0.976858, "min": 0.431018}, "location": {"width": 619, "top": 439, "height": 28, "left": 401}, "words": "研究0102和0103富马酸替诺福韦二呋酯组≥1%受试者报告"}, {"probability": {"variance": 0.000184, "average": 0.991473, "min": 0.95311}, "location": {"width": 319, "top": 470, "height": 26, "left": 401}, "words": "的3/4级实验室异常(0~48周)"}, {"probability": {"variance": 0.008816, "average": 0.951625, "min": 0.70595}, "location": {"width": 201, "top": 519, "height": 22, "left": 602}, "words": "高马酸替诺福韦二吡呋酯"}, {"probability": {"variance": 0.062093, "average": 0.871798, "min": 0.373452}, "location": {"width": 93, "top": 517, "height": 22, "left": 880}, "words": "阿德韦酯"}, {"probability": {"variance": 0.047012, "average": 0.858777, "min": 0.427185}, "location": {"width": 43, "top": 545, "height": 17, "left": 678}, "words": "N=42"}, {"probability": {"variance": 7e-06, "average": 0.997242, "min": 0.993569}, "location": {"width": 33, "top": 544, "height": 18, "left": 924}, "words": "215"}, {"probability": {"variance": 5e-06, "average": 0.998218, "min": 0.992124}, "location": {"width": 190, "top": 581, "height": 23, "left": 206}, "words": "任何≥3级实验室异常"}, {"probability": {"variance": 0.002169, "average": 0.957905, "min": 0.892537}, "location": {"width": 19, "top": 582, "height": 19, "left": 918}, "words": "139"}, {"probability": {"variance": 0.001958, "average": 0.980598, "min": 0.800978}, "location": {"width": 316, "top": 617, "height": 23, "left": 205}, "words": "肌酸激酶(M:>990U/L;F:>845U/L"}, {"probability": {"variance": 0.001448, "average": 0.957572, "min": 0.919518}, "location": {"width": 21, "top": 581, "height": 56, "left": 692}, "words": "9%"}, {"probability": {"variance": 9.1e-05, "average": 0.993644, "min": 0.966362}, "location": {"width": 181, "top": 652, "height": 23, "left": 207}, "words": "血清淀粉酶(>175U/L"}, {"probability": {"variance": 1.1e-05, "average": 0.997867, "min": 0.990026}, "location": {"width": 102, "top": 690, "height": 21, "left": 207}, "words": "尿糖(≥3+)"}, {"probability": {"variance": 0, "average": 0.999532, "min": 0.9991}, "location": {"width": 18, "top": 690, "height": 18, "left": 694}, "words": "3%"}, {"probability": {"variance": 0.004622, "average": 0.973782, "min": 0.673711}, "location": {"width": 277, "top": 726, "height": 22, "left": 205}, "words": "AST(M:>180U/L;F:>170U/L)"}, {"probability": {"variance": 0, "average": 0.999486, "min": 0.998977}, "location": {"width": 19, "top": 727, "height": 18, "left": 694}, "words": "4%"}, {"probability": {"variance": 0.000395, "average": 0.979975, "min": 0.960093}, "location": {"width": 19, "top": 726, "height": 19, "left": 922}, "words": "4%"}, {"probability": {"variance": 0.000628, "average": 0.988148, "min": 0.901767}, "location": {"width": 277, "top": 763, "height": 20, "left": 205}, "words": "ALT(M:>215U/L;F:>170U/L)"}, {"probability": {"variance": 0.062069, "average": 0.647281, "min": 0.398145}, "location": {"width": 19, "top": 763, "height": 19, "left": 694}, "words": "0"}, {"probability": {"variance": 0.000366, "average": 0.987396, "min": 0.944304}, "location": {"width": 150, "top": 792, "height": 24, "left": 205}, "words": "M:男性,F:女性"}, {"probability": {"variance": 0.004868, "average": 0.983071, "min": 0.5483}, "location": {"width": 823, "top": 837, "height": 29, "left": 207}, "words": "治疗期间ALT反跳总发生率(即血清ALT大于2X基线值,且大于10XULN,伴有或不"}, {"probability": {"variance": 2.7e-05, "average": 0.997593, "min": 0.969956}, "location": {"width": 791, "top": 867, "height": 28, "left": 207}, "words": "伴有相关症状),富马酸替诺福韦二吡呋酯组(2.6%)与阿德福韦酯组(2%)相似"}, {"probability": {"variance": 0.000946, "average": 0.993886, "min": 0.810208}, "location": {"width": 807, "top": 896, "height": 27, "left": 207}, "words": "ALT反跳常在治疗的前4-8周内出现,并伴 HBV DNA浓度下降。没有受试者显示出失"}, {"probability": {"variance": 2.3e-05, "average": 0.998012, "min": 0.976403}, "location": {"width": 747, "top": 923, "height": 30, "left": 206}, "words": "代偿的证据。未经调整研究药物治疗,典型的ALT反跳在4至8周内基本缓解"}, {"probability": {"variance": 0.003246, "average": 0.985463, "min": 0.654273}, "location": {"width": 814, "top": 975, "height": 27, "left": 207}, "words": "接受富马酸替诺福韦二吡呋酯治疗的拉米夫定耐药的慢性乙肝受试者出现的不良反应"}, {"probability": {"variance": 0.001552, "average": 0.98649, "min": 0.818677}, "location": {"width": 424, "top": 1005, "height": 27, "left": 208}, "words": "与其它成人HBV临床试验中的不良反应一致"}, {"probability": {"variance": 4e-06, "average": 0.998731, "min": 0.992132}, "location": {"width": 309, "top": 1055, "height": 28, "left": 208}, "words": "中国成人慢性乙肝患者临床疗效"}, {"probability": {"variance": 0.001093, "average": 0.990901, "min": 0.791657}, "location": {"width": 782, "top": 1102, "height": 30, "left": 233}, "words": "项随机、双盲、阳性对照试验(研究LOC114648)中,富马酸替诺福韦二吡呋酯与"}, {"probability": {"variance": 2.2e-05, "average": 0.997837, "min": 0.979288}, "location": {"width": 826, "top": 1130, "height": 32, "left": 207}, "words": "阿德福韦酯安全性比较评价显示,富马酸替诺福韦二吡呋酯组治疗48周的中国患者不"}, {"probability": {"variance": 3e-05, "average": 0.997624, "min": 0.970694}, "location": {"width": 813, "top": 1158, "height": 30, "left": 209}, "words": "良反应与其他HBV临床试验相近。最常报告的不良事件为上呼吸道感染,富马酸替诺"}, {"probability": {"variance": 2.1e-05, "average": 0.997455, "min": 0.978775}, "location": {"width": 824, "top": 1186, "height": 29, "left": 209}, "words": "福韦二吡呋酯组8.2%,阿德福韦酯组6.7%。经研究者判断为与研究药物相关的不良事"}, {"probability": {"variance": 0.00027, "average": 0.993663, "min": 0.918453}, "location": {"width": 792, "top": 1217, "height": 29, "left": 208}, "words": "件的发生率富马酸替诺福韦二吡呋酯治疗组(3.9%)、阿德福韦酯组(4.8%9相近"}, {"probability": {"variance": 0.006025, "average": 0.982975, "min": 0.515227}, "location": {"width": 819, "top": 1245, "height": 27, "left": 209}, "words": "两组中均无任何1%以上患者报告的与药物相关的不良反应。富马酸替诺福韦一吡呋酯"}, {"probability": {"variance": 1e-05, "average": 0.998411, "min": 0.984741}, "location": {"width": 826, "top": 1272, "height": 28, "left": 209}, "words": "组16%、阿德福韦酯组10%受试者报告治疗期间出现的3级或4级实验室异常。富马酸"}, {"probability": {"variance": 9.9e-05, "average": 0.994836, "min": 0.958363}, "location": {"width": 796, "top": 1299, "height": 34, "left": 209}, "words": "替诺福韦二吡呋酯组(9%)报告3级/4级ALT异常的受试者比例高于阿德福韦酯组"}, {"probability": {"variance": 0.000122, "average": 0.991715, "min": 0.952272}, "location": {"width": 412, "top": 1332, "height": 28, "left": 223}, "words": "(7%)。本研究中无3级/4级血清肌酐异常"}, {"probability": {"variance": 1e-05, "average": 0.997593, "min": 0.990362}, "location": {"width": 419, "top": 1380, "height": 29, "left": 211}, "words": "成人慢性乙肝和失代偿肝病受试者临床试验"}], "language": 3}